To investigate this effect, we analyzed two pre-treatment biopsies from the same breast tumor and added a temporal dimension by examining a single sample from the tumor collected 16 weeks after aromatase-inhibitor (AI) therapy. Here, CYP19A1 is linked to breast neoplasm.